Phase 1 is the gate where peptide drug-development programs prove out half-life, immunogenicity, and acute tolerability in humans for the first time. Most peptide Phase 1 programs run 12-18 months from IND to topline data — single-ascending-dose and multiple-ascending-dose studies typically enroll 40-90 healthy volunteers or patients across 4-6 escalating dose cohorts. Coverage here tracks the active Phase 1 trials that anchor near-term clinical inflection points across obesity, oncology, and rare-disease peptide programs.
Active Phase 1 programs covered on the site include Avacta's AVA6103 (FAP-exatecan PDC, FOCUS-01 trial, first patient March 2026), MetaVia's DA-1726 (oxyntomodulin analog, Part 3 higher-dose titration data due ADA 2026), BriaCell's Bria-PROS+ (prostate cancer cell immunotherapy, clinical supplies completed May 2026), Aivocode's CAQK (brain-injury tetrapeptide, IND-enabling work ongoing), and a deeper bench of oral peptide platforms from Pinnacle Medicines, Pinnacle Biologics, and Ridgeview Sciences.
Stories here cover first-patient announcements, dose-escalation milestones, and pharmacokinetic readouts that move candidates toward Phase 2. See #clinical-trials, #ind-enabling, and #peptide-drug-conjugate for adjacent threads.
Enveda Biosciences (Boulder, Colorado; AI-enabled natural product discovery platform) continues to draw attention through September 2026 for ENV-308, the first-in-class oral small-molecule mimetic of Lac-Phe (N-lactoyl-phenylalanine, an exercise-produced signaling molecule) whose Phase 1 safety and tolerability data was reported August 18, 2026. The Phase 1 trial in 88 healthy volunteers showed ENV-308 was well-tolerated with low GI side effects and reduced circulating leptin as a biomarker signal that the drug reaches metabolically-active concentrations in humans. In preclinical animal studies, ENV-308 preserved lean muscle during weight loss and prevented weight regain after weight-loss therapy was stopped. Enveda cites the statistic that roughly 1 in 8 U.S. adults have used a GLP-1 medication and most stop within a year for cost, side-effect, or plateau reasons. Phase 2 will test whether ENV-308 helps people maintain weight after stopping GLP-1s. Timeline: realistic earliest approval 2028-2029. ENV-308 joins bimagrumab (Eli Lilly, anti-activin receptor Phase 3), HM17321 (Hanmi-Genentech UCN2 analog, Phase 1), and ARO-INHBE (Arrowhead RNAi, Phase 1/2a) in the muscle-preservation pipeline.
Enveda Biosciences (Boulder, Colorado, AI-enabled natural product discovery platform) reported positive Phase 1 results August 18, 2026 for ENV-308, a first-of-its-kind oral small molecule engineered to mimic the therapeutic effects of Lac-Phe (a hormone released during intense exercise) for the treatment of post-GLP-1 weight regain and lean-mass loss. In the Phase 1 trial (n=88 healthy volunteers), ENV-308 was extremely well tolerated including on gastrointestinal safety, and reduced circulating leptin as an exploratory metabolic-engagement signal. In animal studies, ENV-308 preserved lean muscle during weight loss and prevented weight regain after weight-loss therapy was stopped. Enveda cites the statistic that 1 in 8 U.S. adults use GLP-1 medications and the majority who take them for weight loss stop within one year. Phase 2 will test whether ENV-308 can help people maintain weight after stopping GLP-1s. Not a peptide, but the exercise-mimetic pathway is one of the leading commercial answers to the muscle-preservation and post-discontinuation regain problems that constrain the current peptide obesity therapeutic class.
Vivani Medical (NASDAQ: VANI) continues to progress its long-acting NanoPortal peptide-implant program with two assets in active development. NPM-115 (exenatide implant using NanoPortal technology): LIBERATE-1 first-in-human Phase 1 clinical study completed with a positive safety and tolerability profile plus encouraging performance data on exenatide release from the implant. NPM-139 (novel semaglutide implant): ongoing preclinical study has documented greater than 20% sham-adjusted weight loss for a full year from a single implant administration, with sustained semaglutide exposures documented over 231+ days. Recent preclinical readouts showed sustained semaglutide exposures and greater than 20% sham-adjusted weight loss with a single implant. Phase 1 clinical study initiation for NPM-139 is targeted for H1 2026 pending regulatory clearance. Phase 2 study design is anticipated as a randomized, placebo-controlled, dose-ranging investigation over 4 to 6 months to evaluate weight management in overweight or obese subjects. The long-acting implant delivery format addresses a substantial adherence-and-convenience gap in the current GLP-1 obesity drug class: weekly self-injection adherence in real-world claims data shows 30+ day dose gaps in a substantial share of patients within 12 months, and once-yearly implant dosing would materially change the adherence trajectory. Vivani's NanoPortal platform uses a micron-scale drug reservoir to release peptide payload at zero-order kinetics over extended durations. The category is early-stage but attracts increasing attention as GLP-1 franchise economics push toward longer-acting formats.
Viking Therapeutics (NASDAQ: VKTX) disclosed on the July 29, 2026 Q2 2026 earnings call that VK3019, a novel dual amylin and calcitonin receptor agonist peptide for obesity, has entered Phase 1 clinical development. The candidate extends the company's obesity pipeline beyond the flagship VK2735 (dual GLP-1/GIP agonist). VK2735 status: Phase 3 VANQUISH program in obesity and obesity/type 2 diabetes is fully enrolled and advancing on track; oral VK2735 Phase 3 trials are slated to initiate in Q4 2026, positioning Viking as a potential first-to-market oral dual GLP-1/GIP agonist. A novel maintenance dosing study for VK2735 is nearing completion, with results expected later in Q3 2026 exploring less frequent dosing regimens. Q2 2026 financials: net loss widened to $128.1 million from $65.6 million in Q2 2025 on increased R&D spending, with $502 million in cash and short-term investments down from $706 million at year-end 2025. VK3019 is mechanistically distinct from VK2735: amylin signaling adds brainstem-mediated satiety (via the calcitonin receptor complex with RAMPs) on top of a calcitonin receptor agonism that has a longer development history in postmenopausal osteoporosis (Miacalcin) and Paget's disease. The amylin plus calcitonin combination extends the amylin-analog obesity category anchored by Novo Nordisk's cagrilintide (a component of CagriSema) and the Novo amycretin oral amylin monotherapy program.
Boulevard Bio emerged from stealth on Wednesday August 12, 2026 with $65 million in founding financing from Deerfield Management, naming Georg Schett (one of the pioneers of immune reset in autoimmune disease) as co-founder. The company disclosed a precision-immunology pipeline of three drug candidates anchored by BLVD101, an internally discovered dual BAFF/APRIL-targeting bispecific antibody. Mechanism: BLVD101 is designed to inhibit BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand), two cytokines that promote the proliferation, survival, and maturation of B cells that drive autoimmune disorders. By blocking both cytokines simultaneously, BLVD101 aims to limit the abnormal B cell activity that attacks healthy tissue in autoimmune diseases. Early Phase 1 healthy volunteer data supports a 12-week (quarterly) subcutaneous dosing interval for BLVD101 in IgA nephropathy (IgAN), a positive tolerability and pharmacokinetic profile that would compare favorably against monthly-dosing biologics in adjacent indications. The launch extends the IgAN indication activity that Trutakna and Fabhalta opened up earlier in 2026 with their FDA approvals ten days apart in the same indication category, though those two drugs target the complement pathway (factor B, C5) rather than the B-cell BAFF/APRIL axis that BLVD101 addresses.
Alnylam Pharmaceuticals (NASDAQ: ALNY) confirmed a first-in-human Phase 1 trial of ALN-6222, an investigational subcutaneous siRNA therapeutic in adults with obesity, in a July 22 filing update on ClinicalTrials.gov (NCT07624071). The randomized, double-blind, placebo-controlled, single ascending dose study will enroll approximately 88 participants with a BMI of 30 to less than 40 kg/m² and an HbA1c below 6.5% (excluding participants with diabetes). The primary endpoints are safety and pharmacodynamics; secondary endpoints include changes in body weight and metabolic markers. The molecular target of ALN-6222 has not been publicly disclosed. The trial is set to run through December 2027 at a single site in Mount Royal, Canada. ALN-6222 marks Alnylam's first clinical-stage entry into the obesity therapeutic area, joining a broader wave of nucleic-acid, peptide, and peptide-fusion modalities entering the space beyond the GLP-1 incumbents (Wegovy, Ozempic, Mounjaro, Zepbound) and the Alnylam-PeptiDream peptide-siRNA conjugate collaboration announced in 2021. Alnylam separately reports Q2 2026 earnings later this week and is expected to discuss the ALN-6222 program on the call.
Samsung Bioepis and Korean biotech IntoCell announced Wednesday July 22, 2026 that they have entered into a commercial license agreement for SBE303, one of the antibody-drug conjugate (ADC) candidates the two companies are jointly developing. SBE303 is a next-generation ADC cancer treatment targeting the Nectin-4 protein, combining Samsung Bioepis's proprietary humanized antibody with IntoCell's linker platform and a payload originally developed by IntoCell under patent license from China's Frontline. Samsung Bioepis is currently conducting a global Phase 1 clinical trial of SBE303 in the United States and Korea, with plans to evaluate safety and preliminary efficacy in 149 patients with advanced refractory solid tumors through July 2030. The deal extends Samsung Bioepis's strategic shift from a biosimilar manufacturer to a novel-drug developer, and adds to the July 2026 payload-and-conjugate consolidation wave alongside Novartis's July 6 $1.5 billion Myricx Bio acquisition (NMTi payload platform), Lonza's July 2 Nona Biosciences TfR1 blood-brain-barrier deal, SOTIO's July 14 FDA Fast Track Designation for SOT109 (CDH17 ADC), and Simris Group's July 16 appointment of former Heidelberg Pharma CEO Andreas Pahl to lead its cyanobacterial microcystin ADC payload platform.
Dana-Farber Cancer Institute researchers led by David Reardon (Director, Center for Neuro-Oncology) and Catherine Wu (Chief, Division of Stem Cell Transplantation and Cell Therapies) presented Phase 1 data at ASCO 2026 on NeoVax — a personalized neoantigen peptide vaccine — combined with pembrolizumab in newly diagnosed glioblastoma. The study excluded dexamethasone (an immune suppressant) and added pembrolizumab to enhance anti-tumor activity. Vaccine-stimulated anti-tumor activity was still evident in some patients after one year, with vaccine-specific T cells migrating into the brain and tumors following vaccination. The MGMT-methylated patient subgroup showed median survival meaningfully exceeding historical observations, though the authors emphasized this requires cautious interpretation given the lack of a randomized comparator arm. The timing of pembrolizumab administration didn't affect immune-response stimulation, but pembrolizumab-before-NeoVax-priming may extend overall survival. NeoVax adds to the personalized neoantigen vaccine cohort (BioNTech autogene cevumeran, Moderna intismeran autogene, Evaxion EVX-01) anchoring the broader peptide cancer vaccine field.
Avacta Therapeutics reported unaudited preliminary results for the 12 months ended December 31, 2025 on Tuesday May 19, 2026, and disclosed that the first patient received treatment in FOCUS-01 — the Phase 1 clinical trial of AVA6103, a FAP-activated exatecan peptide-drug conjugate — in March 2026. AVA6103 is the second pre|CISION-enabled candidate in the Avacta clinical pipeline, after AVA6000 (FAP-Dox, which has Phase Ia/Ib data scheduled at ASCO 2026 in salivary gland cancers). The pre|CISION platform attaches a peptide tetrazolyl moiety cleaved by FAP (fibroblast activation protein) overexpressed in cancer-associated fibroblasts, allowing systemic administration of cytotoxic payloads without the dose-limiting toxicity that constrains free exatecan. FOCUS-01 is enrolling adults with advanced solid tumors. AVA6103 expands the platform from doxorubicin (in AVA6000) to exatecan — a topoisomerase I inhibitor with potency advantages in HER2-low and triple-negative breast cancer.
MetaVia confirmed Monday May 18 that three late-breaking abstracts have been accepted at the ADA 2026 Scientific Sessions (June 5-8 New Orleans). DA-1726 is a once-weekly subcutaneous oxyntomodulin analog functioning as a GLP-1R/GCGR dual agonist for obesity and MASH; Phase 1 Part 3 higher-dose titration results will be presented, with full Phase 1 trial data expected in Q4 2026. Vanoglipel (DA-1241) is a first-in-class GPR119 agonist that promotes endogenous release of GLP-1, GIP, and PYY from the gut; the ADA poster covers synergistic preclinical effects in combination with resmetirom (Madrigal's MASH therapy) and with metformin for type 2 diabetes. The three-poster slate positions MetaVia as one of several mid-cap obesity-pipeline names with clinical data inflections clustered into the ADA + ASCO + EASD 2026 calendar.
Asahi Kasei initiated a Phase I trial in Japan of AK1940, a selective TNF receptor 1 antagonist peptide discovered jointly with PeptiDream for autoimmune and inflammatory diseases. The trial will assess PK, safety, and tolerability of single and multiple subcutaneous doses in healthy volunteers; preclinical models showed high TNFR1 selectivity and anti-inflammatory activity without blocking TNFR2 signaling.
A Phase 1 trial published in Nature Medicine showed that FLC-Vac, a therapeutic peptide vaccine targeting the DNAJ-PKAc fusion protein in fibrolamellar hepatocellular carcinoma, combined with nivolumab and ipilimumab achieved 75% disease control (9/12 patients) and 25% partial response rate. All responders showed tumor-specific T cell responses.